Heterogeneous brain distribution of bumetanide following systemic administration in rats.
NKCC1
blood–brain barrier
cerebral blood flow
efflux transport
loop diuretic
Journal
Biopharmaceutics & drug disposition
ISSN: 1099-081X
Titre abrégé: Biopharm Drug Dispos
Pays: England
ID NLM: 7911226
Informations de publication
Date de publication:
01 Jun 2024
01 Jun 2024
Historique:
revised:
19
04
2024
received:
22
02
2024
accepted:
16
05
2024
medline:
1
6
2024
pubmed:
1
6
2024
entrez:
1
6
2024
Statut:
aheadofprint
Résumé
Bumetanide is used widely as a tool and off-label treatment to inhibit the Na-K-2Cl cotransporter NKCC1 in the brain and thereby to normalize intra-neuronal chloride levels in several brain disorders. However, following systemic administration, bumetanide only poorly penetrates into the brain parenchyma and does not reach levels sufficient to inhibit NKCC1. The low brain penetration is a consequence of both the high ionization rate and plasma protein binding, which restrict brain entry by passive diffusion, and of brain efflux transport. In previous studies, bumetanide was determined in the whole brain or a few brain regions, such as the hippocampus. However, the blood-brain barrier and its efflux transporters are heterogeneous across brain regions, so it cannot be excluded that bumetanide reaches sufficiently high brain levels for NKCC1 inhibition in some discrete brain areas. Here, bumetanide was determined in 14 brain regions following i.v. administration of 10 mg/kg in rats. Because bumetanide is much more rapidly eliminated by rats than humans, its metabolism was reduced by pretreatment with piperonyl butoxide. Significant, up to 5-fold differences in regional bumetanide levels were determined with the highest levels in the midbrain and olfactory bulb and the lowest levels in the striatum and amygdala. Brain:plasma ratios ranged between 0.004 (amygdala) and 0.022 (olfactory bulb). Regional brain levels were significantly correlated with local cerebral blood flow. However, regional bumetanide levels were far below the IC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
Informations de copyright
© 2024 The Author(s). Biopharmaceutics & Drug Disposition published by John Wiley & Sons Ltd.
Références
Alnaqbi, N., Mohammad, M. G., Hamoudi, R., Mabondzo, A., & Harati, R. (2023). Molecular heterogeneity of the brain endothelium. Current Issues in Molecular Biology, 45(4), 3462–3478. https://doi.org/10.3390/cimb45040227
Alvarez‐Leefmans, F. J. (2012). Intracellular chloride regulation. In N. Sperelakis (Ed.), Cell physiology sourcebook: Essentials of membrane biophysics (4th ed., pp. 221–259). Academic Press.
Beck, T., & Krieglstein, J. (1987). Local cerebral glucose utilization and local cerebral blood flow in conscious rats after administration of flunarizine. Naunyn‐Schmiedeberg’s Archives of Pharmacology, 335(6), 680–685. https://doi.org/10.1007/bf00166986
Blaesse, P., Airaksinen, M. S., Rivera, C., & Kaila, K. (2009). Cation‐chloride cotransporters and neuronal function. Neuron, 61(6), 820–838. https://doi.org/10.1016/j.neuron.2009.03.003
Brandt, C., Nozadze, M., Heuchert, N., Rattka, M., & Löscher, W. (2010). Disease‐modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. Journal of Neuroscience, 30(25), 8602–8612. https://doi.org/10.1523/jneurosci.0633‐10.2010
Brandt, C., Seja, P., Töllner, K., Römermann, K., Hampel, P., Kalesse, M., Kipper, A., Feit, P. W., Lykke, K., Toft‐Bertelsen, T. L., Paavilainen, P., Spoljaric, I., Puskarjov, M., Macaulay, N., Kaila, K., & Löscher, W. (2018). Bumepamine, a brain‐permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti‐seizure efficacy. Neuropharmacology, 143, 186–204. https://doi.org/10.1016/j.neuropharm.2018.09.025
Cao, L., Coventry, B., Goreshnik, I., Huang, B., Sheffler, W., Park, J. S., Jude, K. M., Markovic, I., Kadam, R. U., Verschueren, K. H. G., Verstraete, K., Walsh, S. T. R., Bennett, N., Phal, A., Yang, A., Kozodoy, L., DeWitt, M., Picton, L., Miller, L., … Baker, D. (2022). Design of protein‐binding proteins from the target structure alone. Nature, 605(7910), 551–560. https://doi.org/10.1038/s41586‐022‐04654‐9
Chowdhury, E. A., Noorani, B., Alqahtani, F., Bhalerao, A., Raut, S., Sivandzade, F., & Cucullo, L. (2021). Understanding the brain uptake and permeability of small molecules through the BBB: A technical overview. Journal of Cerebral Blood Flow and Metabolism, 41, 1797–1820.
Cleary, R. T., Sun, H., Huynh, T., Manning, S. M., Li, Y., Rotenberg, A., Talos, D. M., Kahle, K. T., Jackson, M., Rakhade, S. N., Berry, G., & Jensen, F. E. (2013). Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PLoS One, 8(3), e57148. https://doi.org/10.1371/journal.pone.0057148
Dehaye, J. P., Nagy, A., Premkumar, A., & Turner, R. J. (2003). Identification of a functionally important conformation‐sensitive region of the secretory Na+‐K+‐2Cl‐cotransporter (NKCC1). Journal of Biological Chemistry, 278(14), 11811–11817. https://doi.org/10.1074/jbc.m213148200
Delpire, E., & Gagnon, K. B. (2018). Na(+) ‐K(+) ‐2Cl(‐) cotransporter (NKCC) physiological function in nonpolarized cells and transporting epithelia. Comprehensive Physiology, 8, 871–901.
Donovan, M. D., O'Brien, F. E., Boylan, G. B., Cryan, J. F., & Griffin, B. T. (2015). The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: An integrated in vivo microdialysis study in the rat. Journal of Pharmaceutics & Pharmacology, 67(4), 501–510. https://doi.org/10.1111/jphp.12341
Donovan, M. D., Schellekens, H., Boylan, G. B., Cryan, J. F., & Griffin, B. T. (2016). In vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide. European Journal of Pharmacology, 770, 117–125. https://doi.org/10.1016/j.ejphar.2015.12.001
Ferguson, C. S., & Tyndale, R. F. (2011). Cytochrome P450 enzymes in the brain: Emerging evidence of biological significance. Trends in Pharmacological Sciences, 32(12), 708–714. https://doi.org/10.1016/j.tips.2011.08.005
Frey, H.‐H., & Löscher, W. (1978). Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology, 17(8), 637–642. https://doi.org/10.1016/0028‐3908(78)90160‐0
Gleave, K., Lissenden, N., Chaplin, M., Choi, L., & Ranson, H. (2021). Piperonyl butoxide (PBO) combined with pyrethroids in insecticide‐treated nets to prevent malaria in Africa. Cochrane Database of Systematic Reviews, 5(6), CD012776. https://doi.org/10.1002/14651858.cd012776.pub3
Gustafsson, S., Sehlin, D., Lampa, E., Hammarlund‐Udenaes, M., & Loryan, I. (2019). Heterogeneous drug tissue binding in brain regions of rats, Alzheimer's patients and controls: Impact on translational drug development. Scientific Reports, 9(1), 5308. https://doi.org/10.1038/s41598‐019‐41828‐4
Halladay, S. C., Carter, D. E., & Sipes, I. G. (1978). A relationship between the metabolism of bumetanide and its diuretic activity in the rat. Drug Metabolism & Disposition, 6, 45–49.
Hampel, P., Römermann, K., Gramer, M., & Löscher, W. (2021). The search for brain‐permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic‐pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain. Epilepsy and Behavior, 114, 107616. https://doi.org/10.1016/j.yebeh.2020.107616
Hampel, P., Römermann, K., Macaulay, N., & Löscher, W. (2018). Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium‐potassium‐chloride‐cotransporter human variants hNKCC1A and hNKCC1B. Scientific Reports, 8(1), 9877. https://doi.org/10.1038/s41598‐018‐27995‐w
Hoeppner, T. J. (1990). The anticonvulsant valproic acid concentrates in the olfactory bulb: Selective laminar localization. Brain Research, 532(1–2), 326–328. https://doi.org/10.1016/0006‐8993(90)91776‐d
Horton, R. W., Pedley, T. A., & Meldrum, B. S. (1980). Regional cerebral blood flow in the rat as determined by particle distribution and by diffusible tracer. Stroke, 11(1), 39–44. https://doi.org/10.1161/01.str.11.1.39
Javaheri, S., Davis, C., & Rogers, D. H. (1993). Ionic composition of cisternal CSF in acute respiratory acidosis: Lack of effect of large dose bumetanide. Journal of Neurochemistry, 61(4), 1525–1529. https://doi.org/10.1111/j.1471‐4159.1993.tb13648.x
Johne, M., Käufer, C., Römermann, K., Gailus, B., Gericke, B., & Löscher, W. (2021). A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia. Epilepsia, 62(6), 1460–1471. https://doi.org/10.1111/epi.16912
Johne, M., Römermann, K., Hampel, P., Gailus, B., Theilmann, W., Ala‐Kurikka, T., Kaila, K., & Löscher, W. (2021). Phenobarbital and midazolam suppress neonatal seizures in a non‐invasive rat model of birth asphyxia while bumetanide is ineffective. Epilepsia, 62(4), 920–934. https://doi.org/10.1111/epi.16778
Kahle, K. T., Simard, J. M., Staley, K. J., Nahed, B. V., Jones, P. S., & Sun, D. (2009). Molecular mechanisms of ischemic cerebral edema: Role of electroneutral ion transport. Physiology, 24(4), 257–265. https://doi.org/10.1152/physiol.00015.2009
Kahle, K. T., Staley, K. J., Nahed, B. V., Gamba, G., Hebert, S. C., Lifton, R. P., & Mount, D. B. (2008). Roles of the cation‐chloride cotransporters in neurological disease. Nature Clinical Practice Neurology, 4(9), 490–503. https://doi.org/10.1038/ncpneuro0883
Kaila, K., Price, T. J., Payne, J. A., Puskarjov, M., & Voipio, J. (2014). Cation‐chloride cotransporters in neuronal development, plasticity and disease. Nature Reviews Neuroscience, 15(10), 637–654. https://doi.org/10.1038/nrn3819
Karlgren, M., Vildhede, A., Norinder, U., Wisniewski, J. R., Kimoto, E., Lai, Y., Haglund, U., & Artursson, P. (2012). Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): Influence of protein expression on drug‐drug interactions. Journal of Medicinal Chemistry, 55(10), 4740–4763. https://doi.org/10.1021/jm300212s
Kharod, S. C., Kang, S. K., & Kadam, S. D. (2019). Off‐label use of bumetanide for brain disorders: An overview. Frontiers in Neuroscience, 13, 310. https://doi.org/10.3389/fnins.2019.00310
Kimura, R., Deguchi, H., & Murata, T. (1983). Absorption, distribution and excretion of piperonyl butoxide in rats. Journal of the Food Hygienic Society of Japan, 24(3), 319–323. https://doi.org/10.3358/shokueishi.24.319
Kolis, S. J., Williams, T. H., & Schwartz, M. A. (1976). Identification of the urinary metabolites of 14C‐bumetanide in the rat and their excretion by rats and dogs. Drug Metabolism & Disposition, 4, 169–176.
Kücker, S., Töllner, K., Piechotta, M., & Gernert, M. (2010). Kindling as a model of temporal lobe epilepsy induces bilateral changes in spontaneous striatal activity. Neurobiology of Disease, 37(3), 661–672. https://doi.org/10.1016/j.nbd.2009.12.002
Kuo, C. H., Tune, B. M., & Hook, J. B. (1983). Effect of piperonyl butoxide on organic anion and cation transport in rabbit kidneys. Proceedings of the Society for Experimental Biology and Medicine, 174(2), 165–171. https://doi.org/10.3181/00379727‐174‐41720
Kurki, S. N., Uvarov, P., Pospelov, A. S., Trontti, K., Hübner, A. K., Srinivasan, R., Watanabe, M., Hovatta, I., Hübner, C. A., Kaila, K., & Virtanen, M. A. (2023). Expression patterns of NKCC1 in neurons and non‐neuronal cells during cortico‐hippocampal development. Cerebral Cortex, 33(10), 5906–5923. https://doi.org/10.1093/cercor/bhac470
Li, Y., Cleary, R., Kellogg, M., Soul, J. S., Berry, G. T., & Jensen, F. E. (2011). Sensitive isotope dilution liquid chromatography/tandem mass spectrometry method for quantitative analysis of bumetanide in serum and brain tissue. Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences, 879(13–14), 998–1002. https://doi.org/10.1016/j.jchromb.2011.02.018
Loryan, I., Melander, E., Svensson, M., Payan, M., König, F., Jansson, B., & Hammarlund‐Udenaes, M. (2016). In‐depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target‐site concentration in CNS regions: Link to spatial receptor occupancy. Molecular Psychiatry, 21(11), 1527–1536. https://doi.org/10.1038/mp.2015.229
Löscher, W. (1999). Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action. Progress In Neurobiology (Oxford), 58(1), 31–59. https://doi.org/10.1016/s0301‐0082(98)00075‐6
Löscher, W. (2002). Basic pharmacology of valproate: A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs, 16(10), 669–694. https://doi.org/10.2165/00023210‐200216100‐00003
Löscher, W., Annies, R., & Hönack, D. (1991). The N‐methyl‐D‐aspartate receptor antagonist MK‐801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neuroscience Letters, 128(2), 191–194. https://doi.org/10.1016/0304‐3940(91)90258‐u
Löscher, W., & Friedman, A. (2020). Structural, molecular and functional alterations of the blood‐brain barrier during epileptogenesis and epilepsy: A cause, consequence or both? International Journal of Molecular Sciences, 21(2), 591. https://doi.org/10.3390/ijms21020591
Löscher, W., Hönack, D., & Gramer, M. (1989). Use of inhibitors of gamma‐aminobutyric acid (GABA) transaminase for the estimation of GABA turnover in various brain regions of rats: A reevaluation of aminooxyacetic acid. Journal of Neurochemistry, 53(6), 1737–1750. https://doi.org/10.1111/j.1471‐4159.1989.tb09239.x
Löscher, W., & Kaila, K. (2022). CNS pharmacology of NKCC1 inhibitors. Neuropharmacology, 205, 108910. https://doi.org/10.1016/j.neuropharm.2021.108910
Löscher, W., Puskarjov, M., & Kaila, K. (2013). Cation‐chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology, 69, 62–74. https://doi.org/10.1016/j.neuropharm.2012.05.045
Löscher, W., Vetter, M., Müller, F., Böhme, G., & Stoltenburg‐Didinger, G. (1984). Development of a synaptosomal model to determine drug‐induced in vivo changes in GABA‐levels of nerve endings in 11 brain regions of the rat. Neurochemistry International, 6(4), 441–451. https://doi.org/10.1016/0197‐0186(84)90113‐x
Luptáková, D., Vallianatou, T., Nilsson, A., Shariatgorji, R., Hammarlund‐Udenaes, M., Loryan, I., & Andrén, P. E. (2021). Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood‐brain barrier. Molecular Psychiatry, 26(12), 7732–7745. https://doi.org/10.1038/s41380‐021‐01267‐y
Magnussen, M. P., & Eilertsen, E. (1974). Species differences in the diuretic activity and metabolism of bumetanide. Naunyn‐Schmiedeberg’s Archives of Pharmacology, 282(Suppl.), R61.
Mokgokong, R., Wang, S., Taylor, C. J., Barrand, M. A., & Hladky, S. B. (2014). Ion transporters in brain endothelial cells that contribute to formation of brain interstitial fluid. Pflügers Archiv, 466(5), 887–901. https://doi.org/10.1007/s00424‐013‐1342‐9
Morris, M. E., & Felmlee, M. A. (2008). Overview of the proton‐coupled MCT (SLC16A) family of transporters: Characterization, function and role in the transport of the drug of abuse gamma‐hydroxybutyric acid. The AAPS Journal, 10(2), 311–321. https://doi.org/10.1208/s12248‐008‐9035‐6
Murakami, Y., Kohyama, N., Kobayashi, Y., Ohbayashi, M., Ohtani, H., Sawada, Y., & Yamamoto, T. (2005). Functional characterization of human monocarboxylate transporter 6 (SLC16A5). Drug Metabolism & Disposition, 33, 1845–1851. https://doi.org/10.1124/dmd.105.005264
Nagar, S., & Korzekwa, K. (2012). Commentary: Nonspecific protein binding versus membrane partitioning: It is not just semantics. Drug Metabolism & Disposition, 40(9), 1649–1652. https://doi.org/10.1124/dmd.112.046599
Nguyen, T. D., Ishibashi, M., Sinha, A. S., Watanabe, M., Kato, D., Horiuchi, H., Wake, H., & Fukuda, A. (2023). Astrocytic NKCC1 inhibits seizures by buffering Cl(‐) and antagonizing neuronal NKCC1 at GABAergic synapses. Epilepsia, 64(12), 3389–3403. https://doi.org/10.1111/epi.17784
Oh, S. W., & Han, S. Y. (2015). Loop diuretics in clinical practice. Electrolyte Blood Press, 13(1), 17–21. https://doi.org/10.5049/ebp.2015.13.1.17
Olsen, U. B. (1977). The pharmacology of bumetanide. Acta Pharmacologica et Toxicologica, 41(s3), 1–29. https://doi.org/10.1111/j.1600‐0773.1977.tb03209.x
Ostergaard, E. H., Magnussen, M. P., Nielsen, C. K., Eilertsen, E., & Frey, H. H. (1972). Pharmacological properties of 3‐n‐butylamino‐4‐phenoxy‐5‐sulfamylbenzoic acid (Bumetanide), a new potent diuretic. Arzneimittelforschung, 22, 66–72.
Pardridge, W. M. (2020). Blood‐brain barrier and delivery of protein and gene therapeutics to brain. Frontiers in Aging Neuroscience, 11, 373. https://doi.org/10.3389/fnagi.2019.00373
Pochini, L., Galluccio, M., Scalise, M., Console, L., & Indiveri, C. (2019). OCTN: A small transporter subfamily with great relevance to human pathophysiology, drug discovery, and diagnostics. SLAS Discovery, 24(2), 89–110. https://doi.org/10.1177/2472555218812821
Puskarjov, M., Kahle, K. T., Ruusuvuori, E., & Kaila, K. (2014). Pharmacotherapeutic targeting of cation‐chloride cotransporters in neonatal seizures. Epilepsia, 55(6), 806–818. https://doi.org/10.1111/epi.12620
Römermann, K., Fedrowitz, M., Hampel, P., Kaczmarek, E., Töllner, K., Erker, T., Sweet, D. H., & Löscher, W. (2017). Multiple blood‐brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain. Neuropharmacology, 117, 182–194. https://doi.org/10.1016/j.neuropharm.2017.02.006
Roush, G. C., Kaur, R., & Ernst, M. E. (2014). Diuretics: A review and update. Journal of Cardiovascular Pharmacology and Therapeutics, 19(1), 5–13. https://doi.org/10.1177/1074248413497257
Russell, J. M. (2000). Sodium‐potassium‐chloride cotransport. Physiological Reviews, 80(1), 211–276. https://doi.org/10.1152/physrev.2000.80.1.211
Savardi, A., Borgogno, M., Narducci, R., La Sala, G., Ortega, J. A., Summa, M., Armirotti, A., Bertorelli, R., Contestabile, A., De Vivo, M., & Cancedda, L. (2020). Discovery of a small molecule drug candidate for selective NKCC1 inhibition in brain disorders. Chem, 6(8), 2073–2096. https://doi.org/10.1016/j.chempr.2020.06.017
Schobben, F., van der Kleijn, E., & Vree, T. B. (1980). Therapeutic monitoring of valproic acid. Therapeutic Drug Monitoring, 2(1), 61–71. https://doi.org/10.1097/00007691‐198001000‐00008
Schulte, J. T., Wierenga, C. J., & Bruining, H. (2018). Chloride transporters and GABA polarity in developmental, neurological and psychiatric conditions. Neuroscience & Biobehavioral Reviews, 90, 260–271. https://doi.org/10.1016/j.neubiorev.2018.05.001
Schwartz, M. A. (1981). Metabolism of bumetanide. The Journal of Clinical Pharmacology, 21(11), 555–563. https://doi.org/10.1002/j.1552‐4604.1981.tb05664.x
Shen, D. D. (1999). Valproate: Absorption, distribution, and excretion. In W. Löscher (Ed.), Valproate (pp. 77–90). Birkhäuser.
Töllner, K., Brandt, C., Römermann, K., & Löscher, W. (2015). The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide. European Journal of Pharmacology, 746, 167–173. https://doi.org/10.1016/j.ejphar.2014.11.019
Töllner, K., Brandt, C., Töpfer, M., Brunhofer, G., Erker, T., Gabriel, M., Feit, P. W., Lindfors, J., Kaila, K., & Löscher, W. (2014). A novel prodrug‐based strategy to increase effects of bumetanide in epilepsy. Annals of Neurology, 75(4), 550–562. https://doi.org/10.1002/ana.24124
Töpfer, M., Töllner, K., Brandt, C., Twele, F., Bröer, S., & Löscher, W. (2014). Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy. European Journal of Neuroscience, 39(4), 673–687. https://doi.org/10.1111/ejn.12424
Ueki, S., Araki, Y., & Watanabe, S. (1977). Changes in sensitivity of mice to anticonvulsant drugs following bilateral olfactory bulb ablations. The Japanese Journal of Pharmacology, 27(2), 183–192. https://doi.org/10.1254/jjp.27.183
VanWert, A. L., Gionfriddo, M. R., & Sweet, D. H. (2010). Organic anion transporters: Discovery, pharmacology, regulation and roles in pathophysiology. Biopharmaceutics & Drug Disposition, 31, 1–71. https://doi.org/10.1002/bdd.693
Vijay, N., & Morris, M. E. (2014). Role of monocarboxylate transporters in drug delivery to the brain. Current Pharmaceutical Design, 20(10), 1487–1498. https://doi.org/10.2174/13816128113199990462
Villabona‐Rueda, A., Erice, C., Pardo, C. A., & Stins, M. F. (2019). The evolving concept of the blood brain barrier (BBB): From a single static barrier to a heterogeneous and dynamic relay center. Frontiers in Cellular Neuroscience, 13, 405. https://doi.org/10.3389/fncel.2019.00405
Wang, J., Lisanza, S., Juergens, D., Tischer, D., Watson, J. L., Castro, K. M., Ragotte, R., Saragovi, A., Milles, L. F., Baek, M., Anishchenko, I., Yang, W., Hicks, D. R., Expòsit, M., Schlichthaerle, T., Chun, J. H., Dauparas, J., Bennett, N., Wicky, B. I. M., … Baker, D. (2022). Scaffolding protein functional sites using deep learning. Science, 377(6604), 387–394. https://doi.org/10.1126/science.abn2100
Wang, S., Zhang, X. Q., Song, C. G., Xiao, T., Zhao, M., Zhu, G., & Zhao, C. S. (2015). In vivo effects of bumetanide at brain concentrations incompatible with NKCC1 inhibition on newborn DGC structure and spontaneous EEG seizures following hypoxia‐induced neonatal seizures. Neuroscience, 286, 203–215. https://doi.org/10.1016/j.neuroscience.2014.11.031
Ward, A., & Heel, R. C. (1984). Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs, 28(5), 426–464. https://doi.org/10.2165/00003495‐198428050‐00003
Wargo, K. A., & Banta, W. M. (2009). A comprehensive review of the loop diuretics: Should furosemide be first line? The Annals of Pharmacotherapy, 43(11), 1836–1847. https://doi.org/10.1345/aph.1m177
Wilhelm, I., Nyul‐Toth, A., Suciu, M., Hermenean, A., & Krizbai, I. A. (2016). Heterogeneity of the blood‐brain barrier. Tissue Barriers, 4(1), e1143544. https://doi.org/10.1080/21688370.2016.1143544
Zeisel, A., Hochgerner, H., Lönnerberg, P., Johnsson, A., Memic, F., van der Zwan, J., Häring, M., Braun, E., Borm, L. E., La Manno, G., Codeluppi, S., Furlan, A., Lee, K., Skene, N., Harris, K. D., Hjerling‐Leffler, J., Arenas, E., Ernfors, P., Marklund, U., & Linnarsson, S. (2018). Molecular architecture of the mouse nervous system. Cell, 174(4), 999–1014. https://doi.org/10.1016/j.cell.2018.06.021
Zhao, R., & Pollack, G. M. (2009). Regional differences in capillary density, perfusion rate, and P‐glycoprotein activity: A quantitative analysis of regional drug exposure in the brain. Biochemical Pharmacology, 78(8), 1052–1059. https://doi.org/10.1016/j.bcp.2009.06.001